Fascaplysin has stronger anti-cancer effects than other CDK4 inhibitors on lung cancer cells that are wild-type or null for Rb, indicating that unknown target molecules might be involved in the antitumor activity of fascaplysin [43]. Here, CDK4 is linked to lung carcinoma.